Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1995;85:304-313
© 1995 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grady, D
Right arrow Articles by Petitti, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grady, D
Right arrow Articles by Petitti, D

Articles

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

D Grady, T Gebretsadik, K Kerlikowske, V Ernster, and D Petitti

OBJECTIVE: To assess the association of unopposed estrogen or estrogen plus progestin and the risk of developing endometrial cancer or dying of that disease. DATA SOURCES: A literature search of English-language studies was performed using MEDLINE, a review of bibliographies, and consultations with experts. METHODS OF STUDY SELECTION: We identified 30 studies with adequate controls and risk estimates. DATA EXTRACTION AND SYNTHESIS: Risk estimates were extracted by two authors and summarized using meta-analytic methods. The summary relative risk (RR) was 2.3 for estrogen users compared to nonusers (95% confidence interval [CI] 2.1-2.5), with a much higher RR associated with prolonged duration of use (RR 9.5 for 10 or more years). The summary RR of endometrial cancer remained elevated 5 or more years after discontinuation of unopposed estrogen therapy (RR 2.3). Interrupting estrogen for 5-7 days per month was not associated with lower risk than daily use. Users of unopposed conjugated estrogen had a greater increase in RR of developing endometrial cancer than users of synthetic estrogens. The risk for endometrial cancer death was elevated among unopposed estrogen users (RR 2.7, 95% CI 0.9-8.0). Among estrogen plus progestin users, cohort studies showed a decreased risk of endometrial cancer (RR 0.4), whereas case-control studies showed a small increase (RR 1.8). CONCLUSIONS: Endometrial cancer risk increases substantially with long duration of unopposed estrogen use, and this increased risk persists for several years after discontinuation of estrogen. Although not statistically significant, the risk of death from endometrial cancer among unopposed estrogen users is increased, similar to the increased risk of developing the disease. Data regarding risk for endometrial cancer among estrogen plus progestin users are limited and conflicting.


This article has been cited by other articles:


Home page
 Obstet GynecolHome page
B. Ettinger, P. Kenemans, S. R. Johnson, M. Mol-Arts, S. Van Os, W. Seifert, P. J.M. Verweij, and S. R. Cummings
Endometrial Effects of Tibolone in Elderly, Osteoporotic Women
Obstet. Gynecol., September 1, 2008; 112(3): 653 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Menopause IntHome page
M. Rees and S. Hope
Use of unopposed systemic estrogen therapy in non-hysterectomized women: a population-based study in the UK
Menopause Int, June 1, 2008; 14(2): 83 - 84.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. L. Deming, W. Zheng, W.-H. Xu, Q. Cai, Z. Ruan, Y.-B. Xiang, and X.-O. Shu
UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 563 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
B. S. Saltzman, J. A. Doherty, D. A. Hill, S. A. Beresford, L. F. Voigt, C. Chen, and N. S. Weiss
Diabetes and Endometrial Cancer: An Evaluation of the Modifying Effects of Other Known Risk Factors
Am. J. Epidemiol., March 1, 2008; 167(5): 607 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Corrao, A. Zambon, V. Conti, F. Nicotra, C. La Vecchia, C. Fornari, G. Cesana, P. Contiero, G. Tagliabue, R. E. Nappi, et al.
Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation
Ann. Onc., January 1, 2008; 19(1): 150 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
T. R. Rebbeck, A. B. Troxel, S. Norman, G. Bunin, A. DeMichele, R. Schinnar, J. A. Berlin, and B. L. Strom
Pharmacogenetic Modulation of Combined Hormone Replacement Therapy by Progesterone-Metabolism Genotypes in Postmenopausal Breast Cancer Risk
Am. J. Epidemiol., December 15, 2007; 166(12): 1392 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. V. Lacey Jr.
Ovarian Cancer and Menopausal Hormone Therapy: More Data and New Questions
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2524 - 2525.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Olsen, C. J. Bain, S. J. Jordan, C. M. Nagle, A. C. Green, D. C. Whiteman, P. M. Webb, and Australian Cancer Study (Ovarian Cancer) and Austr
Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2321 - 2330.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al.
A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. A. Booth and B. R. Lucchesi
Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1408 - H1415.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S.-C. Chang, J. V. Lacey Jr., L. A. Brinton, P. Hartge, K. Adams, T. Mouw, L. Carroll, A. Hollenbeck, A. Schatzkin, and M. F. Leitzmann
Lifetime Weight History and Endometrial Cancer Risk by Type of Menopausal Hormone Use in the NIH-AARP Diet and Health Study
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 723 - 730.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
D. Grady, B. Cohen, J. Tice, M. Kristof, A. Olyaie, and G. F. Sawaya
Ineffectiveness of Sertraline for Treatment of Menopausal Hot Flushes: A Randomized Controlled Trial
Obstet. Gynecol., April 1, 2007; 109(4): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. F. Archer, S. Hendrix, J. C. Gallagher, J. Rymer, S. Skouby, A. Ferenczy, W. den Hollander, V. Stathopoulos, F. A. Helmond, and for the Tibolone Histology of the Endometrium and
Endometrial Effects of Tibolone
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 911 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
A. Z. Steiner, M. Xiang, W. J. Mack, D. Shoupe, J. C. Felix, R. A. Lobo, and H. N. Hodis
Unopposed Estradiol Therapy in Postmenopausal Women: Results From Two Randomized Trials
Obstet. Gynecol., March 1, 2007; 109(3): 581 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. H. Olson, E. V. Bandera, and I. Orlow
Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review
Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Grady
Management of Menopausal Symptoms
N. Engl. J. Med., November 30, 2006; 355(22): 2338 - 2347.
[Full Text] [PDF]

Home page
 Am J EpidemiolHome page
B. L. Strom, R. Schinnar, A. L. Weber, G. Bunin, J. A. Berlin, M. Baumgarten, A. DeMichele, S. C. Rubin, M. Berlin, A. B. Troxel, et al.
Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer
Am. J. Epidemiol., October 15, 2006; 164(8): 775 - 786.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al.
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
W. Y. Chen, J. E. Manson, S. E. Hankinson, B. Rosner, M. D. Holmes, W. C. Willett, and G. A. Colditz
Unopposed estrogen therapy and the risk of invasive breast cancer.
Arch Intern Med, May 8, 2006; 166(9): 1027 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss
Inflammation and Endometrial Cancer: A Hypothesis
Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2840 - 2847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. R. Rebbeck, T. Friebel, T. Wagner, H. T. Lynch, J. E. Garber, M. B. Daly, C. Isaacs, O. I. Olopade, S. L. Neuhausen, L. van 't Veer, et al.
Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
J. Clin. Oncol., November 1, 2005; 23(31): 7804 - 7810.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
N.R.E. Hampton, M.C.P. Rees, D.G. Lowe, I. Rauramo, D. Barlow, and J. Guillebaud
Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women
Hum. Reprod., September 1, 2005; 20(9): 2653 - 2660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. V. Lacey Jr., L. A. Brinton, J. H. Lubin, M. E. Sherman, A. Schatzkin, and C. Schairer
Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1724 - 1731.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
U.S. Preventive Services Task Force*
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force
Ann Intern Med, May 17, 2005; 142(10): 855 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. Bray, I. dos Santos Silva, H. Moller, and E. Weiderpass
Endometrial Cancer Incidence Trends in Europe: Underlying Determinants and Prospects for Prevention
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1132 - 1142.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
S. R. Johnson, B. Ettinger, J. L. Macer, K. E. Ensrud, J. Quan, and D. Grady
Uterine and Vaginal Effects of Unopposed Ultralow-Dose Transdermal Estradiol
Obstet. Gynecol., April 1, 2005; 105(4): 779 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
M. D. Althuis, K. S. Moghissi, C. L. Westhoff, B. Scoccia, E. J. Lamb, J. H. Lubin, and L. A. Brinton
Uterine Cancer after Use of Clomiphene Citrate to Induce Ovulation
Am. J. Epidemiol., April 1, 2005; 161(7): 607 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
D. Grady, B. Ettinger, E. Moscarelli, L. Plouffe Jr, S. Sarkar, A. Ciaccia, and S. Cummings
Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Obstet. Gynecol., October 1, 2004; 104(4): 837 - 844.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
Ovarian, Endometrial, and Colorectal Cancers
Obstet. Gynecol., October 1, 2004; 104(4_suppl): 77S - 84S.
[Full Text] [PDF]

Home page
 Obstet GynecolHome page
B. Ettinger, K. E. Ensrud, R. Wallace, K. C. Johnson, S. R. Cummings, V. Yankov, E. Vittinghoff, and D. Grady
Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial
Obstet. Gynecol., September 1, 2004; 104(3): 443 - 451.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. E. Wood, T. C. Register, M. S. Anthony, N. D. Kock, and J. M. Cline
Breast and Uterine Effects of Soy Isoflavones and Conjugated Equine Estrogens in Postmenopausal Female Monkeys
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3462 - 3468.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
C. N. Wathen, D. S. Feig, J. W. Feightner, B. L. Abramson, and A. M. Cheung
Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care
Can. Med. Assoc. J., May 11, 2004; 170(10): 1535 - 1537.
[Full Text] [PDF]

Home page
 JAMAHome page
S. B. Hulley and D. Grady
The WHI Estrogen-Alone Trial--Do Things Look Any Better?
JAMA, April 14, 2004; 291(14): 1769 - 1771.
[Full Text] [PDF]

Home page
 JAMAHome page
H. D. Nelson
Postmenopausal Estrogen for Treatment of Hot Flashes: Clinical Applications
JAMA, April 7, 2004; 291(13): 1621 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Armstrong, J. S. Schwartz, T. Randall, S. C. Rubin, and B. Weber
Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
J. Clin. Oncol., March 15, 2004; 22(6): 1045 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
H. Nakamura, T. Kimura, H. Ikegami, K. Ogita, S. Koyama, K. Shimoya, T. Tsujie, M. Koyama, Y. Kaneda, and Y. Murata
Highly efficient and minimally invasive in-vivo gene transfer to the mouse uterus using haemagglutinating virus of Japan (HVJ) envelope vector
Mol. Hum. Reprod., October 1, 2003; 9(10): 603 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Baselga, A. Llombart-Cussac, M. Bellet, V. Guillem-Porta, N. Enas, K. Krejcy, E. Carrasco, L. Kayitalire, M. Kuta, A. Lluch, et al.
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
Ann. Onc., September 1, 2003; 14(9): 1383 - 1390.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. I. Li, K. E. Malone, P. L. Porter, N. S. Weiss, M.-T. C. Tang, K. L. Cushing-Haugen, and J. R. Daling
Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
JAMA, June 25, 2003; 289(24): 3254 - 3263.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Deng, G. L. Shipley, D. S. Loose-Mitchell, G. M. Stancel, R. Broaddus, J. H. Pickar, and P. J. A. Davies
Coordinate Regulation of the Production and Signaling of Retinoic Acid by Estrogen in the Human Endometrium
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2157 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Yasui, S. Matsui, Y.R.S. Laxmi, N. Suzuki, S. Y. Kim, S. Shibutani, and T. Matsuda
Mutagenic events induced by 4-hydroxyequilin in supF shuttle vector plasmid propagated in human cells
Carcinogenesis, May 1, 2003; 24(5): 911 - 917.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. H. Humphries and S. Gill
Risks and benefits of hormone replacement therapy: The evidence speaks
Can. Med. Assoc. J., April 15, 2003; 168(8): 1001 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. L. Riggs and L. C. Hartmann
Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice
N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629.
[Full Text] [PDF]

Home page
 BMJHome page
J. Rymer, R. Wilson, and K. Ballard
Making decisions about hormone replacement therapy
BMJ, February 8, 2003; 326(7384): 322 - 326.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. Kaaks, A. Lukanova, and M. S. Kurzer
Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review
Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
U.S. Preventive Services Task Force*
Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale
Ann Intern Med, November 19, 2002; 137(10): 834 - 839.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
N Kazerouni, C Schairer, H B Friedman, J V Lacey Jr, and M H Greene
Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study
J. Med. Genet., November 1, 2002; 39(11): 826 - 832.
[Full Text] [PDF]

Home page
 JAMAHome page
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan
Postmenopausal Hormone Replacement Therapy: Scientific Review
JAMA, August 21, 2002; 288(7): 872 - 881.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. L. Noller
Estrogen Replacement Therapy and Risk of Ovarian Cancer
JAMA, July 17, 2002; 288(3): 368 - 369.
[Full Text] [PDF]

Home page
 JAMAHome page
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, R. Knopp, M. Lowery, S. Satterfield, H. Schrott, et al.
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
JAMA, July 3, 2002; 288(1): 58 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. Zhao, Q. Chen, and R. D. Brinton
Neuroprotective and Neurotrophic Efficacy of Phytoestrogens in Cultured Hippocampal Neurons
Experimental Biology and Medicine, July 1, 2002; 227(7): 509 - 519.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Wickerham, B. Fisher, N. Wolmark, J. Bryant, J. Costantino, L. Bernstein, and C. D. Runowicz
Association of Tamoxifen and Uterine Sarcoma
J. Clin. Oncol., June 1, 2002; 20(11): 2758 - 2760.
[Full Text] [PDF]

Home page
 JAMAHome page
D. Grady
A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy
JAMA, April 24, 2002; 287(16): 2130 - 2137.
[Full Text] [PDF]

Home page
 JAMAHome page
M. A. Hlatky, D. Boothroyd, E. Vittinghoff, P. Sharp, M. A. Whooley, and for the HERS Research Group
Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy: Results From the Heart and Estrogen/Progestin Replacement Study (HERS) Trial
JAMA, February 6, 2002; 287(5): 591 - 597.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. McNagny, N. K. Wenger, N. Hilmy, S. Banarer, M. Barton, R. K. Dubey, S. R. Davis, J. E. Manson, and K. A. Martin
Postmenopausal Hormone-Replacement Therapy
N. Engl. J. Med., January 3, 2002; 346(1): 63 - 65.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. E. Hale, C. L. Hughes, and J. M. Cline
Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. E. Burdette, J. Liu, D. Lantvit, E. Lim, N. Booth, K. P. L. Bhat, S. Hedayat, R. B. Van Breemen, A. I. Constantinou, J. M. Pezzuto, et al.
Trifolium pratense (Red Clover) Exhibits Estrogenic Effects In Vivo in Ovariectomized Sprague-Dawley Rats
J. Nutr., January 1, 2002; 132(1): 27 - 30.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Manson and K. A. Martin
Postmenopausal Hormone-Replacement Therapy
N. Engl. J. Med., July 5, 2001; 345(1): 34 - 40.
[Full Text] [PDF]

Home page
 Int J EpidemiolHome page
E. Barrett-Connor and C. A Stuenkel
Hormone replacement therapy (HRT)-- risks and benefits
Int. J. Epidemiol., June 1, 2001; 30(3): 423 - 426.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K M Feeley and M Wells
Hormone replacement therapy and the endometrium
J. Clin. Pathol., June 1, 2001; 54(6): 435 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
P. A. Newcomb, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer
Fracture History and Risk of Breast and Endometrial Cancer
Am. J. Epidemiol., June 1, 2001; 153(11): 1071 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. G. Glazier and M. A. Bowman
A Review of the Evidence for the Use of Phytoestrogens as a Replacement for Traditional Estrogen Replacement Therapy
Arch Intern Med, May 14, 2001; 161(9): 1161 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page